China's National Medical Products Administration (NMPA) has approved Hong Kong-based Harbour BioMed's Investigational New Drug (IND) application for HBM4003, the next generation anti-CTLA-4 antibody in combination with PD-1 antibody/chemotherapy intended for the treatment of patients with advanced NSCLC and solid tumours, it was reported on Thursday.
The study is to assess the safety, tolerability, PK/PD, and anti-tumour activity of the product in combination with PD-1 antibody, with or without chemotherapy, in subjects with advanced NSCLC and other solid tumours.
The product is the fully human anti-CTLA-4 monoclonal heavy chain only antibody generated from Harbour Mice. It has already received US FDA and China NMPA IND approvals of the mono therapy and another combination therapy in China. It has completed patient dosing in several patients in its ongoing phase I study in Australia.
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA